1. Home
  2. CLGN vs ITRM Comparison

CLGN vs ITRM Comparison

Compare CLGN & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLGN
  • ITRM
  • Stock Information
  • Founded
  • CLGN 2004
  • ITRM 2015
  • Country
  • CLGN Israel
  • ITRM Ireland
  • Employees
  • CLGN N/A
  • ITRM N/A
  • Industry
  • CLGN Industrial Specialties
  • ITRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • CLGN Health Care
  • ITRM Health Care
  • Exchange
  • CLGN Nasdaq
  • ITRM Nasdaq
  • Market Cap
  • CLGN 37.4M
  • ITRM 35.6M
  • IPO Year
  • CLGN N/A
  • ITRM 2018
  • Fundamental
  • Price
  • CLGN $1.82
  • ITRM $1.02
  • Analyst Decision
  • CLGN Strong Buy
  • ITRM Strong Buy
  • Analyst Count
  • CLGN 2
  • ITRM 2
  • Target Price
  • CLGN $12.50
  • ITRM $7.00
  • AVG Volume (30 Days)
  • CLGN 12.7K
  • ITRM 575.7K
  • Earning Date
  • CLGN 05-28-2025
  • ITRM 05-13-2025
  • Dividend Yield
  • CLGN N/A
  • ITRM N/A
  • EPS Growth
  • CLGN N/A
  • ITRM N/A
  • EPS
  • CLGN N/A
  • ITRM N/A
  • Revenue
  • CLGN $515,000.00
  • ITRM N/A
  • Revenue This Year
  • CLGN $2,177.67
  • ITRM N/A
  • Revenue Next Year
  • CLGN $56.52
  • ITRM $108.39
  • P/E Ratio
  • CLGN N/A
  • ITRM N/A
  • Revenue Growth
  • CLGN N/A
  • ITRM N/A
  • 52 Week Low
  • CLGN $1.82
  • ITRM $0.81
  • 52 Week High
  • CLGN $6.75
  • ITRM $3.02
  • Technical
  • Relative Strength Index (RSI)
  • CLGN 23.18
  • ITRM 42.76
  • Support Level
  • CLGN $2.00
  • ITRM $0.88
  • Resistance Level
  • CLGN $2.40
  • ITRM $1.14
  • Average True Range (ATR)
  • CLGN 0.21
  • ITRM 0.11
  • MACD
  • CLGN -0.01
  • ITRM -0.01
  • Stochastic Oscillator
  • CLGN 3.59
  • ITRM 25.93

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: